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A B S T R A C T
Purpose: A synonymous C to T variant at position 3435 (c.3435C>T) is one common polymorphism of the
multidrug resistant 1 (MDR1) gene, which encodes the major transmembrane efﬂux transporter
P-glycoprotein. It has been suggested that this polymorphism, and more speciﬁcally the 3435CC
genotype, may be associated with the response to antiepileptic drug treatment. Here we wished to
examine the role of such a candidate variant in a cohort of 175 patients (98 women and 76 men;
mean  SD age: 47.90  17.64) with temporal lobe epilepsy (TLE).
Methods: Patients were classiﬁed according to whether they had drug-responsive (n = 134) or drug-
resistant (n = 41) epilepsy. We also enrolled 175 healthy controls (93 women and 82 men; mean  SD
age: 72.5  6.8), matched for sex and ethnicity.
Results: Patients and controls were genotyped for detection of the 3435C>T polymorphism, but the
analysis showed no signiﬁcant association between the CC genotype and the risk of drug-resistant
epilepsy.
Conclusion: These ﬁndings rule out the MDR1 c.3435C>T polymorphism having a major role or
increasing the risk of drug-resistance suggesting a revision is required to determine the contribution of
this polymorphism in predicting drug response in epilepsy.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is one of the most prevalent chronic neurological
disorders, affecting approximately 1–2% of the population.1
About one third of patients with epilepsy have poor seizure
control and experience recurrent seizure events despite appro-
priate therapy with antiepileptic drugs (AEDs).2 The mechanisms
underlying the resistance to AEDs in the epilepsy treatment are
still not well-understood, although efforts to predict pharma-
coresistance have revealed several risk factors such as an early
onset of epilepsy, etiology, type of epilepsy, and environmental* Corresponding author at: Cattedra ed U.O. di Neurologia, Universita` degli Studi
‘‘Magna Graecia’’ Catanzaro, Campus Universitario di Germaneto, 88100 Catanzaro,
Italy. Tel.: +39 0961 3647270; fax: +39 0961 3697177.
E-mail address: a.gambardella@unicz.it (A. Gambardella).
http://dx.doi.org/10.1016/j.seizure.2014.09.010
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights refactors.3 Moreover, genetic variants are supposed to play an
important role in the development of pharmacoresistance in
patients with epilepsy.
Growing evidence would indicate that an increase of functional
expression of multidrug transporters produces pharmacokinetic
changes that modify the access of AEDs to central nervous system
targets.4 Genetic polymorphisms in these transporters could
account for their increased expression and/or functional activity.5
P-glycoprotein (P-gp) is the most studied protein among the ATP-
binding cassette (ABC) efﬂux transporters. The ABC subfamily B
member 1 transporter (ABCB1) gene, also known as multidrug
resistance 1 (MDR1), encodes this transmembrane transporter. In
recent years, according to the single nucleotide polymorphism
(SNP) database maintained by the National Center for Biotechnol-
ogy Information (NCBI), more than 50 SNPs have been identiﬁed
that may alter the expression of P-gp or its protective physiological
function. A silent mutation in the MDR1gene, c. 3435C>Tserved.
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protein or alter the protein structure and substrate afﬁnity.6
Several studies have focused on this common SNP to explore the
association with disease development and drag response in
epilepsy but none have been conclusive.7,8
In the light of these controversial ﬁndings, the aim of the
present study was to investigate whether c.3435C>T polymor-
phism is more prevalent in patients with epilepsy versus control
subjects, and whether this gene may serve as a biomarker for
pharmacoresistance in TLE.
2. Materials and methods
2.1. Patients
A total of 175 patients (98 women and 76 men; mean  SD
age: 47.90  17.64) with temporal lobe epilepsy (TLE) were
included in this study. Data and evaluation procedures on our
TLE patients have been reported in greater detail elsewhere.9–10 All
patients received a diagnosis of non-lesional TLE, based on
comprehensive clinical, neuropsychological, electroencephalo-
graphic, and brain MRI evaluations. The diagnosis of TLE was
mainly based on typical temporal auras and/or interictal EEG
discharges with a maximum over the temporal lobes. In all patients,
brain MR images were obtained using sequences and slices to
optimize visual detection of mesial temporal structures. Based on
the MR study, the TLE was classiﬁed as non-lesional if no focal mass
lesions such as cerebral tumors, cortical dysgenesis, vascular
lesions or malformations, or post-traumatic scars were detected.
TLE patients with neuroimaging evidence of mesial temporal
sclerosis were included. Brain MRI study revealed evidence of
hippocampal sclerosis (Hs) in 32/175 (18%) patients.
In all patients, the most utilized AEDs were carbamazepine,
oxcarbazepine, lamotrigine or topiramate as monotherapy or in
combination. According to the International League against
Epilepsy,11 drug-resistance was deﬁned as the failure of
adequate trials of two tolerated, appropriately chosen and
administered AEDs (whether as monotherapy or in combination)
to achieve seizure freedom. Patients were classiﬁed according
to whether they had drug-responsive (n = 134) or drug-
resistant (n = 41) epilepsy. Neurological examinations were
unremarkable in all patients. None of our patients had mental
retardation.
We also enrolled 175 healthy controls (93 women and 82 men;
mean  SD age: 72.5  6.8), matched for sex and ethnicity. Patients
and controls were genotyped for detection of the c.3435C>T
polymorphism using TaqMan Allelic Discrimination assays, on an
Applied Biosystems PCR platform. All patients and controls were
Caucasian and were born in Italy. All tested individuals signed the
informed consent for the genetic testing.Table 1
Genotypic and allelic distributions of the MDR1 c.3435C>T polymorphism in relation 
c.3435C>T polymorphism AED responsive
(n = 134)
AED resistant
(n = 41)
CTRLs 
Genotype
CC 45 (33.6%) 13 (31.7%) 48 (27
CT 64 (47.8%) 21 (51.2%) 98 (56
TT 25 (18.7%) 7 (17.1%) 29 (16
c.3435C>T polymorphism AED responsive
(n = 268)
AED resistant
(n = 82)
CTRLs 
Allele
C 154 (57.5%) 47 (57.3%) 194 (5
T 114 (42.5%) 35 (42.7%) 156 (42.2. Genotyping and mutation analysis
Genomic DNA was extracted from the whole blood using
Wizard Genomic DNA puriﬁcation kit according to the instructions
of the supplier (Promega, Madison, WI). Samples were genotyped
for the c.3435C>T (rs1045642) polymorphism (GeneBank:
NM_000927.4) by TaqMan based allelic discrimination assay
(Applied Biosystems, Foster City, CA, USA). Assay conditions were
in accordance with manufacturers’ protocols. Fluorescence out-
puts were quantiﬁed in real time by using a 7900HT Real Time PCR
System, and the data were analyzed using SDS software, version
2.2.2 (Applied Biosystems).
2.3. Statistical analysis
Allelic and genotype frequencies were estimated by direct
counting. A Chi square (x2) test was used to evaluate for deviation
of genotype frequencies from Hardy–Weinberg equilibrium. The
frequency of alleles and genotypes between patients and controls
were compared using x2 test. Starting from contingency tables
constructed were calculated Odds Ratios (ORs) and their 95%
conﬁdence intervals (CIs). To test the hypothesis of equality of
means between the ages of drug-resistant and drug-responsive
patients and controls we used the one-way analysis of variance,
followed by Student’s t-test for multiple comparisons, correcting
the resulting p-value according to the Bonferroni method. Odds
ratios and Conﬁdence intervals were calculated according to a
multivariate logistic regression model adjusted for age and sex.
Statistical analysis was performed with Statistical Package for
Social Science software (SPSS, version 12.0, Chicago, IL, USA) for
Windows.
3. Results
No signiﬁcant deviations from Hardy–Weinberg equilibrium
were observed in epilepsy patients (p = 0.93). Moreover, our
sample gave sufﬁcient statistical power (>0.80) to detect the
difference at the 0.05 (two-tailed) level. Table 1 shows the
genotype and allele frequencies of the polymorphisms in the MDR1
gene for both drug-resistant and drug-responsive epilepsy
patients. The distribution of MDR1 c.3435 C>T genotypes within
drug-resistant and drug-responsive groups were not signiﬁcantly
different from that under Hardy–Weinberg equilibrium
(p = 0.76 and p = 0.79, respectively). No statistically signiﬁcant
differences were detected for the genotype and allele frequencies
of the polymorphisms in the MDR1 gene between the drug-
resistant and drug-responsive groups (p > 0.05). Moreover, there
was non-signiﬁcant odds ratio (Table 1), indicating that response
to treatment was not affected by the presence or absence of the
MDR1 polymorphism.to AED response.
(n = 175) OR 95% CI
(responsive vs CTRL)
OR 95% CI
(resistant vs CTRL)
p-Value
.4%) 1.0 1.0 0.705
.0%) 0.697 (0.416–1.165) 0.791 (0.365–1.714)
.6%) 0.920 (0.470–1.801) 0.891 (0.319–2.491)
(n = 350) OR 95% CI
(responsive vs CTRL)
OR 95% CI
(resistant vs CTRL)
p-Value
5.4%) 1.0 1.0 0.867
4.6%) 0.921 (0.6681.269) 0.926 (0.570–1.505)
Table 2
Studies of MDR1 c.3435C>T polymorphism in relation to drug-resistance among epilepsy patients and controls based on the ethnicity.
Studies Country Ethnicity Drug-resistant (N of patients) Drug-responsive (N. of patients) Control
(N of subjects)
Results
Chen L et al. (2007) China Asian 50 164 – Negative
Wang SY et al. (2008) China Asian 40 40 40 Negative
Gao X et al. (2009) China Asian 70 62 62 Negative
Von Stulpnagel C et al. (2009) Germany Caucasian 160 71 319 Negative
Alpman A et al. (2010) Turkey Caucasian 38 – 87 Negative
Dong L et al. (2011) China Asian 157 193 368 Negative
Emich-Widera E et al. (2013) Poland Caucasian 60 25 100 Negative
Saygi S et al. (2014) Turkey Caucasian 59 60 76 Negative
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The mechanisms of drug resistance in epilepsy have not been
established. Various genetic polymorphisms in the MDR1 gene
could be linked with altered in vivo transport activity of P-gp,
which could be a facilitator in drug-resistant epilepsy.5 It has been
speculated that the common SNP c.3435C>T in the MDR1 gene,
speciﬁcally the 3435CC genotype, is associated with drug
resistance to anticonvulsants.8 Although several association
studies on the MDR1 gene with drug disposition and disease
susceptibility have been completed to date, the data remain
unclear and incongruous. Therefore, in the present study, we
investigated the common SNP c.3435C>T in the MDR1 gene in
drug-resistant and drug-responsive epilepsy patients. Results of
the present study demonstrated that genotype and allele
frequencies of c.3435C>T polymorphisms of the MDR1 gene did
not differ between drug-responsive and drug resistant epilepsy
patients. The results from various studies focusing on the role of
MDR1 c.3435C>T polymorphism in AED responsiveness are
conﬂicting.7,8 Consistent with the present study, several studies
have found no signiﬁcant associations between drug-resistance
epilepsy and the MDR1 c. 3435C>T polymorphism (Table 2). The
differences observed in these reports may be due to the ethnic
differences in genotype/allele frequencies, because genetic poly-
morphisms often vary between ethnic groups.
In conclusion, we failed to show an association between the
c.3435C>T polymorphism and the risk of drug-resistant epilepsy
in the study population. The limitation of the current study is the
small sample size. So, our results cannot deﬁnitively rule out a role
for this gene, although derived from a small but ethnically
homogeneous sample size, but provides further evidence that
although the MRD1 gene has been highly investigated and plays
many important roles, it is unlikely that the polymorphism
c.3435C>T plays a major role in the development of epilepsy or in
drug resistance to anticonvulsants. Despite the biological plausi-
bility, several studies, including our own, have now failed to
conﬁrm a relationship between the c.3435C>T polymorphism and
drug resistance. The limited contribution of a SNP should also betaken into account. Because the inherited component of the
response to drugs is typically polygenic,12 the impact of a single
gene may be confounded by inﬂuences from other genes and by
environmental factors. It remains to be determined whether
haplotypes in the MDR1 gene play a role in epilepsy susceptibility
or in the risk of drug-resistance.
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